(Q37827222)

23 August 2017

1 reference

title

Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder (English)

1 reference

23 August 2017

Pierre Blier

1

1 reference

23 August 2017

Claude Blondeau

series ordinal

2

1 reference

23 August 2017

publication date

1 January 2011

1 reference

Journal of Affective Disorders

23 August 2017

published in

1 reference

23 August 2017

volume

128 Suppl 1

1 reference

23 August 2017

page(s)

S3-10

1 reference

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Aripiprazole augmentation in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Is there a role for 5-HT1A agonists in the treatment of depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Differential physiological effects of a low dose and high doses of venlafaxine in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

The role of dopamine in the pathophysiology of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Involvement of glutamate neurotransmission and N-methyl-d-aspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptor agonists: an electrophysiological study in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Strategy to Accelerate or Augment the Antidepressant Response and for An Early Onset of SSRI Activity. Adjunctive Amisulpride to Fluvoxamine in Major Depressive Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Aripiprazole as an adjunctive treatment for refractory major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

An open study of aripiprazole and escitalopram for psychotic major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

5-HT7 receptor antagonists as a new class of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Placebo-controlled efficacy of antidepressants in continuation treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Residual symptoms in depressed patients who respond acutely to fluoxetine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Quetiapine XR: current status for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

Medication augmentation after the failure of SSRIs for depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970003-9

7 January 2021

10.1016/S0165-0327(11)70003-9

Identifiers

DOI

1 reference

23 August 2017

1 reference